Kaposi Sarcoma - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Pipeline Review, H2 2016, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape.

Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kaposi Sarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kaposi Sarcoma (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Kaposi Sarcoma.

Kaposi Sarcoma (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kaposi Sarcoma (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kaposi Sarcoma (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Kaposi Sarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Kaposi Sarcoma - Overview 8
Pipeline Products for Kaposi Sarcoma - Comparative Analysis 9
Kaposi Sarcoma - Therapeutics under Development by Companies 10
Kaposi Sarcoma - Therapeutics under Investigation by Universities/Institutes 11
Kaposi Sarcoma - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Kaposi Sarcoma - Products under Development by Companies 15
Kaposi Sarcoma - Products under Investigation by Universities/Institutes 16
Kaposi Sarcoma - Companies Involved in Therapeutics Development 17
Aphios Corp 17
AstraZeneca Plc 18
Biogenomics Limited 19
Cannabis Science Inc 20
Cell Medica Ltd 21
CytRx Corp 22
Tumorend LLC 23
Vironika LLC 24
Kaposi Sarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
aldoxorubicin hydrochloride - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
brolucizumab - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
CM-101 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CSTATI-1 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Dermos - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
doxorubicin - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
interferon alfa-2a - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
interferon alfa-2b - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
selumetinib sulfate - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecule for Kaposi's Sarcoma - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Synthetic Peptide to Inhibit HAUSP for Lymphoma and Kaposi Sarcoma - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Kaposi Sarcoma - Dormant Projects 65
Kaposi Sarcoma - Discontinued Products 67
Kaposi Sarcoma - Product Development Milestones 68
Featured News & Press Releases 68
Jun 06, 2016: CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting 68
May 26, 2016: $1.8 Million Fast-Track NIH SBIR Grant for Manocept Immunotherapeutics Evaluation in Kaposi's Sarcoma Awarded to Navidea 69
May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update 70
Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016 71
Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi's Sarcoma 72
Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages 72
Jun 29, 2015: CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 74
May 28, 2015: Delenex Presents Anti-Tumor Activity of DLX1008 75
Jan 20, 2015: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients 75
Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma 75
Jan 23, 2014: CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi's Sarcoma 76
Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I 77
Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma 78
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi's Sarcoma 79
Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1 80
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 81
Disclaimer 82

List of Tables

Number of Products under Development for Kaposi Sarcoma, H2 2016 8
Number of Products under Development for Kaposi Sarcoma - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Comparative Analysis by Unknown Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Kaposi Sarcoma - Pipeline by Aphios Corp, H2 2016 17
Kaposi Sarcoma - Pipeline by AstraZeneca Plc, H2 2016 18
Kaposi Sarcoma - Pipeline by Biogenomics Limited, H2 2016 19
Kaposi Sarcoma - Pipeline by Cannabis Science Inc, H2 2016 20
Kaposi Sarcoma - Pipeline by Cell Medica Ltd, H2 2016 21
Kaposi Sarcoma - Pipeline by CytRx Corp, H2 2016 22
Kaposi Sarcoma - Pipeline by Tumorend LLC, H2 2016 23
Kaposi Sarcoma - Pipeline by Vironika LLC, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Kaposi Sarcoma - Dormant Projects, H2 2016 65
Kaposi Sarcoma - Dormant Projects (Contd..1), H2 2016 66
Kaposi Sarcoma - Discontinued Products, H2 2016 67